CN115461084B - 安全性高的非层状液晶形成性组合物 - Google Patents

安全性高的非层状液晶形成性组合物

Info

Publication number
CN115461084B
CN115461084B CN202180011394.9A CN202180011394A CN115461084B CN 115461084 B CN115461084 B CN 115461084B CN 202180011394 A CN202180011394 A CN 202180011394A CN 115461084 B CN115461084 B CN 115461084B
Authority
CN
China
Prior art keywords
mono
liquid crystal
enoyl
phospholipid
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180011394.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN115461084A (zh
Inventor
田畑泰彦
村上隆英
藤堂浩明
板仓祥子
杉林坚次
土黑一郎
田能村昌久
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Farnex Inc
Original Assignee
Farnex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farnex Inc filed Critical Farnex Inc
Publication of CN115461084A publication Critical patent/CN115461084A/zh
Application granted granted Critical
Publication of CN115461084B publication Critical patent/CN115461084B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/30—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with trihydroxylic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/33—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with hydroxy compounds having more than three hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/533—Monocarboxylic acid esters having only one carbon-to-carbon double bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202180011394.9A 2020-01-27 2021-01-27 安全性高的非层状液晶形成性组合物 Active CN115461084B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2020-011237 2020-01-27
JP2020011237 2020-01-27
JP2020-211758 2020-12-21
JP2020211758 2020-12-21
PCT/JP2021/002917 WO2021153635A1 (ja) 2020-01-27 2021-01-27 安全性の高い非ラメラ液晶形成性組成物

Publications (2)

Publication Number Publication Date
CN115461084A CN115461084A (zh) 2022-12-09
CN115461084B true CN115461084B (zh) 2026-03-27

Family

ID=77079915

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180011394.9A Active CN115461084B (zh) 2020-01-27 2021-01-27 安全性高的非层状液晶形成性组合物

Country Status (5)

Country Link
US (1) US20230105725A1 (https=)
EP (1) EP4098281A4 (https=)
JP (2) JP7761929B2 (https=)
CN (1) CN115461084B (https=)
WO (1) WO2021153635A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004059470A (ja) * 2002-07-26 2004-02-26 Kanebo Ltd 養毛料
WO2014178256A1 (ja) * 2013-05-01 2014-11-06 株式会社ファルネックス 癒着防止剤

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312814A (en) * 1992-12-09 1994-05-17 Bristol-Myers Squibb Co. α-phosphonocarboxylate squalene synthetase inhibitors
US7846903B2 (en) 2004-10-19 2010-12-07 National Institute Of Advanced Industrial Science And Technology Type II cubic liquid crystal composition
KR101245022B1 (ko) * 2005-01-21 2013-03-19 카무러스 에이비 약제학적 지질 조성물
RU2532165C2 (ru) * 2008-09-22 2014-10-27 Дзе Проктер Энд Гэмбл Компани Определенные разветвленные альдегиды, спирты, поверхностно -активные вещества и потребительские продукты на их основе
JP5207420B2 (ja) 2009-12-25 2013-06-12 株式会社ケムジェネシス 低粘度液晶化合物
JP2012017318A (ja) * 2010-06-07 2012-01-26 Nikko Chemical Co Ltd 液晶及びそれを含有する皮膚外用剤
MX350929B (es) * 2011-12-05 2017-09-26 Camurus Ab Formulaciones peptidicas robustas de liberación controlada.
WO2014101051A1 (en) * 2012-12-27 2014-07-03 Kimberly-Clark Worldwide, Inc. Water soluble farnesol analogs and their use
KR101586789B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
KR101586791B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 ＧｎＲＨ 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
KR101601035B1 (ko) * 2013-02-28 2016-03-08 주식회사 종근당 키토산 및 액상결정 형성 물질을 포함하는 유전자 전달용 조성물
US10814351B2 (en) 2013-08-12 2020-10-27 The Boeing Company High-viscosity sealant application system
JP2019193684A (ja) * 2016-09-05 2019-11-07 株式会社ファルネックス 油分を含むエマルションを用いた癒着防止剤
JP2019099478A (ja) * 2017-11-30 2019-06-24 株式会社ファルネックス 非ラメラ液晶再構成能を有する粉末微粒子製剤
AU2019258590B2 (en) * 2018-04-26 2022-09-08 NanoMed Holdings Pty Ltd Gemcitabine amphiphile prodrugs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004059470A (ja) * 2002-07-26 2004-02-26 Kanebo Ltd 養毛料
WO2014178256A1 (ja) * 2013-05-01 2014-11-06 株式会社ファルネックス 癒着防止剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Akie Okada et al..Controlled release of a model hydrophilic high molecular weight compound from injectable non-lamellar liquid crystal formulations containing different types of phospholipids.International Journal of Pharmaceutic.2019,第577卷1-9. *
Controlled release of a model hydrophilic high molecular weight compound from injectable non-lamellar liquid crystal formulations containing different types of phospholipids;Akie Okada et al.;International Journal of Pharmaceutic;20190921;第577卷;1-9 *

Also Published As

Publication number Publication date
CN115461084A (zh) 2022-12-09
WO2021153635A1 (ja) 2021-08-05
JP2026001219A (ja) 2026-01-06
EP4098281A1 (en) 2022-12-07
US20230105725A1 (en) 2023-04-06
EP4098281A4 (en) 2024-03-20
JP7761929B2 (ja) 2025-10-29
JPWO2021153635A1 (https=) 2021-08-05

Similar Documents

Publication Publication Date Title
KR101492361B1 (ko) 바람직하게 ｓａｉｂ와 같은 당 에스테르를 포함하는 지속적인 국소 마취제 조성물
RU2632433C2 (ru) Липидный преконцентрат с замедленным высвобождением фармакологически активного вещества и фармацевтическая композиция, содержащая его
Gupta et al. Glycerosomes: advanced liposomal drug delivery system
CN106691888B (zh) 一种高皮肤滞留光甘草定纳米组合物及其制备方法和用途
EP2992910A1 (en) Adhesion preventing agent
BRPI0111016B1 (pt) Microemulsion water in stable oil, biologically compatible, well tolerated and use of the same
RU2632436C2 (ru) Липидный преконцентрат анионных фармакологически активных веществ с замедленным высвобождением и содержащая его фармацевтическая композиция
KR20140105436A (ko) 위장관을 따라 약물을 표적화 방출하기 위한 pH 감응성 담체, 그로부터의 조성물, 및 이들의 제조 및 사용 방법
KR20120115991A (ko) 담체 조성물
US11992483B2 (en) Emulsions for local anesthetics
KR20210031857A (ko) 약제학적 제제
CN115804771B (zh) 一种具有长效缓释作用的脂质释药系统及其制备方法
RU2535029C2 (ru) Фармацевтическая композиция, содержащая эфир дгк, для парентерального введения
US10149824B2 (en) Reverse hexagonal mesophases (HII) and uses thereof
KR20230013044A (ko) 커플링된 테르펜 컨쥬게이트
CN115461084B (zh) 安全性高的非层状液晶形成性组合物
EP4378452A1 (en) Non-lamellar liquid crystal-forming composition and use thereof
US20100260830A1 (en) Liposomal Formulations of Tocopheryl Amides
RU2448731C2 (ru) Фосфолипидная композиция
PL197412B1 (pl) Preparat liposomowy zawierający dimaleinian 6,9-bis-[(2-aminoetylo)-amino]benzo[g]izochinolino-5,10-dionu
KR102745034B1 (ko) 수분 감응성 졸-겔 상전이 기반 유착방지용 조성물
JPH05501714A (ja) リポソーム組成物
US20230414595A1 (en) Emulsions for local anesthetics
WO2010118200A2 (en) Liposomal formulations of tocopheryl amides
CN121622549A (zh) 一种原位相变凝胶缓释制剂及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant